Surrozen (SRZN) Change in Account Payables (2020 - 2026)
Surrozen (SRZN) recorded quarterly Change in Account Payables of $161000.0 in Q1 2026, up 278.89% quarter-over-quarter from -$90000.0 in Q4 2025, and up 4125.0% on a YoY basis from $3810.7 in Q1 2025.
Surrozen (SRZN) Change in Account Payables (2020 - 2026) Analysis & Trends
Surrozen's Change in Account Payables history runs 7 years deep, the most recent figure standing at $161000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 4125.0% year-over-year to $161000.0; the TTM figure through Mar 2026 stood at $307000.0 (up 89.51% YoY), while the FY2025 annual figure was $142000.0, up 162.28% from the prior year.
- Change in Account Payables was $161000.0 for Q1 2026 at Surrozen, up from -$90000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $327000.0 in Q4 2022 to a low of -$1.8 million in Q1 2022.
- Historically, Change in Account Payables has averaged -$123294.1 across 5 years, with a median of $21000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Change in Account Payables plunged 528.57% in 2025, then jumped 4125.0% in 2026.
- A 5-year view of Change in Account Payables shows it stood at $327000.0 in 2022, then fell by 27.22% to $238000.0 in 2023, then slumped by 91.18% to $21000.0 in 2024, then slumped by 528.57% to -$90000.0 in 2025, then jumped by 278.89% to $161000.0 in 2026.
- The last three Change in Account Payables figures came in at $161000.0 (Q1 2026), -$90000.0 (Q4 2025), and $184000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -9.42 Mn |
| 10 | Surrozen | 239,016.67 | -106.67 Mn | - | 161,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 161,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Dec 31, 2025 | -90,000.00 |
| Dec 31, 2025 | -90,000.00 |
| Sep 30, 2025 | 184,000.00 |
| Sep 30, 2025 | 184,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Mar 31, 2024 | -394,000.00 |
| Mar 31, 2024 | -394,000.00 |
| Dec 31, 2023 | 238,000.00 |
| Dec 31, 2023 | 238,000.00 |